Established in 1984 in Dallas, Texas, Baylor Research Institute (BRI) promotes and supports research to bring innovative treatments from the laboratory workbench to the patient bedside. To achieve this bench-to-bedside concept, the institute focuses on basic science, clinical trials, healthcare effectiveness and quality of care research.

Dedicated to patient care, award-winning scientists and medical professionals at BRI work to understand the origin of a disease, identify potential treatments or preventative therapies, and enroll patients in research trials. Today, BRI is conducting 800 active research protocols with 250 research investigators, spanning more than 20 medical specialties, and has research frequently reported in major scientific publications as well as at national and international medical meetings.
Our history.

Pioneering and innovation in research are unique characteristics that BRI brings to North Texas communities. The institute identifies and pursues clinically relevant research opportunities aimed at improving health care. The results of the Institute's research-basic, applied and clinical care are reported in major scientific publications and at national and international medical meetings.

Baylor Research Institute participates at BIO International Convention

As a first time exhibitor, Baylor Research Institute attended the BIO International Convention held in Chicago this year at McCormick Place.  During the convention, BRI’s COO, Bernard Brigonnet, and Business Development team partnered with venture capitalists, Pharma and other organizations conducting research to establish relationships for future business opportunities.

Focused on Patients, Bench to Bedside was developed for BRI to showcase top innovations from across the Baylor Health Care System.

Aside from keynote sessions, presentations and breakout sessions at the 2010 BIO International Convention focused on research and development, partnership opportunities, and new business models required to meet global health challenges. This year, the Convention program featured more than 125 sessions in 17 tracks. New tracks for 2010 included Delivery and Manufacturing of Biologics, Global Drug Development and Marketing, Innovations in Vaccines, and MarketPlace Watch. BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 60 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

Today, BRI is conducting 800 active research protocols with 250 research investigators, spanning more than 20 medical specialties.  The following areas in research were highlighted during the BIO International Convention:

• Immunotherapy
• Cancer Vaccine
• HIV Vaccine
• Juvenile Arthritis (SoJIA)
• Gene Therapy
• Pancreatic Islet Transplantation
• Fabry Disease